Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Buy" by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have covered the stock in the last year is $20.40.

A number of equities analysts recently issued reports on ARTV shares. Wedbush reissued an "outperform" rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. Cantor Fitzgerald lowered their target price on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 25th. Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Artiva Biotherapeutics during the 4th quarter worth $52,000. Wells Fargo & Company MN boosted its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after buying an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets grew its position in Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock worth $100,000 after buying an additional 7,151 shares during the period. JPMorgan Chase & Co. purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $166,000. Finally, Deutsche Bank AG acquired a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at approximately $216,000.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $2.44 on Friday. Artiva Biotherapeutics has a 1 year low of $1.78 and a 1 year high of $17.31. The company's fifty day moving average is $3.39 and its two-hundred day moving average is $7.17.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.